Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a pill target Hard-to-Treat bile duct cancers? a new drug puts FGFR2 mutations to the test

NCT ID NCT06160752

Ongoing Disease control Sponsor: Tyra Biosciences, Inc Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Aug 06, 2026 · Updated 3 times

Summary

This early-stage trial is testing an experimental oral drug, TYRA-200, in people with advanced bile duct cancer (intrahepatic cholangiocarcinoma) and other solid tumors that have specific changes in the FGFR2 gene. The study aims to find a safe and effective dose and to see whether the drug can slow or shrink these cancers. Participants take TYRA-200 once daily in 28-day cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an oral drug called TYRA-200 that targets tumors with FGFR2 gene alterations
What this could lead to
If successful, this could lead to a new targeted treatment option for people with advanced bile duct cancer and other solid tumors that have specific FGFR2 gene changes.
What could go wrong
This is an early, first-in-human trial with a small number of participants, so safety and effectiveness are not yet known. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Apert syndrome cholangiocarcinoma intrahepatic cholangiocarcinoma neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTRAHEPATIC CHOLANGIOCARCINOMA LOCALLY ADVANCED CHOLANGIOCARCINOMA METASTATIC CHOLANGIOCARCINOMA SOLID TUMOR

Contacts and locations

Locations

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • The Ohio State University

    Columbus, Ohio, 43210, United States

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • University of California San Francisco (UCSF)

    San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.